Topical 0.5% Moxifloxacin Prevents Endophthalmitis in an Intravitreal Injection Rabbit Model (original) (raw)

Postsurgical Cataract Prophylaxis With Intravitreal “Triamcinolone-Moxifloxacin” May Not Be Optimal For Preventing Endophthalmitis

Eric Romanowski

Eye & Contact Lens: Science & Clinical Practice, 2018

View PDFchevron_right

Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model

Eric Romanowski

American Journal of Ophthalmology, 2004

View PDFchevron_right

Effect of Intravitreal Triamcinolone Acetonide on Susceptibility to Experimental Bacterial Endophthalmitis and Subsequent Response to Treatment

Yannis Paulus

Archives of Ophthalmology, 2005

View PDFchevron_right

Clearance of Intravitreal Moxifloxacin

William Mieler

Investigative Ophthalmology & Visual Science, 2006

View PDFchevron_right

Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required

juan garcia sanchez

Archives of Ophthalmology, 2009

View PDFchevron_right

Effects of intravitreal triamcinolone acetonide injection with and without preservative

Mauricio Maia

British Journal of Ophthalmology, 2007

View PDFchevron_right

Intracameral Vigamox® (Moxifloxacin 0.5%) is Non-Toxic and Effective in Preventing Endophthalmitis in a Rabbit Model

Eric Romanowski

American Journal of Ophthalmology, 2005

View PDFchevron_right

Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis

Steve Arshinoff

Journal of cataract and refractive surgery, 2016

View PDFchevron_right

Noninfectious Endophthalmitis Associated With Intravitreal Triamcinolone Injection

roberto velasquez

Archives of Ophthalmology, 2003

View PDFchevron_right

Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical Antibiotics

Frederick Ferris

Archives of Ophthalmology, 2012

View PDFchevron_right

Vitreous and aqueous penetration of intravitreally and orally administered moxifloxacin in an experimental rabbit model of fungal endophthalmitis

Aysun DİNÇEL

Journal of Pharmacy and Pharmacology, 2013

View PDFchevron_right

Future of Ophthalmic Anti-infective Therapy and the Role of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX®)

Barry Schlech

Survey of Ophthalmology, 2005

View PDFchevron_right

In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment

Marcus Kernt

Journal of Cataract & Refractive Surgery, 2008

View PDFchevron_right

Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration

William Mieler

Transactions of the American Ophthalmological Society, 2004

View PDFchevron_right

Role of topical antibiotics in prophylaxis against endophthalmitis following intravitreal antibiotics

B. Naeem, Ume Sughra

Pakistan Journal of Medical Sciences, 2018

View PDFchevron_right

Acute Endophthalmitis Following Intravitreal Triamcinolone Acetonide Injection* 1

William Mieler

American journal of …, 2003

View PDFchevron_right

Intravitreal clearance of moxifloxacin

William Mieler

Transactions of the American Ophthalmological Society, 2005

View PDFchevron_right

Intracameral Moxifloxacin: In Vitro Safety on Human Ocular Cells

Marcus Kernt, Kirsten Eibl

Cornea, 2009

View PDFchevron_right

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

Ingrid Scott

American Journal of Ophthalmology, 2004

View PDFchevron_right

Cohort Study of Intracameral Moxifloxacin in Postoperative Endophthalmitis Prophylaxis

Virgilio Galvis

Ophthalmology and Eye Diseases, 2014

View PDFchevron_right

Intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery: A case Series

Gaston Gomez Caride

Investigative Ophthalmology & Visual Science, 2013

View PDFchevron_right

Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis

Mehryar Taban

American journal of ophthalmology, 2007

View PDFchevron_right

Overview of the Potency of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX®)

Barry Schlech

Survey of Ophthalmology, 2005

View PDFchevron_right

Intravitreal Triamcinolone Acetonide in the Management of Exogenous Bacterial Endophthalmitis

Milan K. Shah

American Journal of Ophthalmology, 2006

View PDFchevron_right

Topical Antibiotic Prophylaxis and Intravitreal Injections: Impact on the Incidence of Acute Endophthalmitis—A Nationwide Study in France from 2009 to 2018

Florian Baudin

Pharmaceutics

View PDFchevron_right

Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review

Giacomo Toneatto

Eye, 2018

View PDFchevron_right

Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin

Masahiko Fukuda

Clinical Ophthalmology, 2009

View PDFchevron_right

Prophylaxis for Endophthalmitis Following Intravitreal Injection: Antisepsis and Antibiotics

Charles Wykoff

American Journal of Ophthalmology, 2011

View PDFchevron_right

Intravitreal oxacillin in experimental staphylococcal endophthalmitis

Gholam Peyman

Albrecht von Graefes Archiv f�r Klinische und Experimentelle Ophthalmologie, 1975

View PDFchevron_right

The Comparison of Fluoroquinolones to NonFluoroquinolone Antibacterial Agents for the Prevention of Endophthalmitis in a Rabbit Model

Robert Shanks

Journal of Ocular Pharmacology and Therapeutics, 2012

View PDFchevron_right

Vitreous and Aqueous Penetration of Orally Administered Moxifloxacin in Humans

Gaurav Shah

Archives of Ophthalmology, 2006

View PDFchevron_right